Stockholders approve conversion of Series B Preferred at special meeting

Cartesian Therapeutics, Inc.

Special meeting held Sep 20, 2024; 75.9% of outstanding shares represented.
Proposal 1 passed: 12,514,261 FOR, 150,060 AGAINST, 1,650 abstentions (excluding 3,563,247 shares for Nasdaq compliance).
Proposal 2 (adjournment if needed) approved: 16,076,183 FOR, 151,789 AGAINST, 1,246 abstentions.
Approval allows issuance of common stock upon conversion of Series B Non-Voting Convertible Preferred.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.